Aerie Pharmaceuticals announced the appointment of Michelle Senchyna, PhD, as Vice President, Clinical Development and Medical Affairs, reporting to David A. Hollander, MD, MBA, Aerie’s Chief Research & Development Officer.
Dr. Senchyna will lead and direct the clinical development and medical affairs strategy for the company. She most recently served as Executive Director of Ophthalmology at Allergan, where she oversaw the clinical development of pharmaceutical, consumer and device products for anterior and posterior segment diseases. Prior to joining Allergan, Dr. Senchyna held leadership positions in R&D and Medical Affairs at Alcon and Panoptica, with focus on anterior segment and biomarker discovery. She began her career as an Associate Professor at the University of Waterloo, School of Optometry with research focused on ocular surface diseases and contact lens biomaterial development. She is an author on more than 40 peer-reviewed publications, has given more than 60 presentations nationally and internationally, and holds multiple patents. Dr. Senchyna earned both a BSc and PhD from McMaster University.
In connection with her acceptance of the position as Vice President, Clinical Development and Medical Affairs, Dr. Senchyna will receive awards totaling 20,060 stock options and 10,000 shares of restricted stock. The stock options will vest over 4 years, with 25% vesting on the first anniversary of the hire date and the remainder vesting ratably on each of the subsequent 36 monthly anniversaries of the hire date; the restricted stock will vest over a period of 4 years in four equal annual installments on each anniversary of the hire date.